Ilan Ganot, Alesta Therapeutics CEO (Solid Bio)
January 8, 2025 11:00 AM EST
Financing
Startups

Sol­id Bio's for­mer CEO launch­es new rare dis­ease start­up with €65M Se­ries A

Max Gelman

Senior Editor

A new start­up aim­ing to tack­le rare dis­eases de-stealthed Wednes­day morn­ing with a CEO ex­pe­ri­enced in the space.

Ales­ta Ther­a­peu­tics took the wraps off its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Gene edit­ing start­up Scribe Ther­a­peu­tics lets go of staff as it preps for the clin­ic

Astel­las stops de­vel­op­ing au­tol­o­gous cell ther­a­py us­ing tech from Xyphos buy­out

MaaT Phar­ma touts ‘un­prece­dent­ed’ Phase 3 ef­fi­ca­cy of graft-ver­sus-host dis­ease treat­ment

Re­silience cuts 120 em­ploy­ees at a for­mer blue­bird gene ther­a­py site

A service from the Financial Times